GlassScriptPhysician profile
Danielle Steinmetz
NPI 1982101036
$1,584.01
in general payments reported to CMS, 2019-2025
19 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2021: $519 · 2022: $159 · 2023: $143 · 2024: $357 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $277.14 | 2021-2025 | Spravato |
| Esperion Therapeutics, INC. | $250.00 | 2021 | |
| Acadia Pharmaceuticals INC | $193.69 | 2023-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $176.78 | 2024-2025 | Ingrezza |
| Boston Scientific Corporation | $140.11 | 2024 | Watchman Flx |
| Allergan, INC. | $124.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.74 | 2021 | |
| Sumitomo Pharma America, INC. | $52.46 | 2023 | Gemtesa |
| Pfizer INC. | $39.22 | 2023 | |
| Novo Nordisk INC | $36.59 | 2022-2024 | Rybelsus, Ozempic |
| Emd Serono, INC. | $22.06 | 2022 | |
| Abbvie INC. | $20.56 | 2023 | Vraylar |
| Abbott Laboratories | $18.91 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.86 | 2024 | Rexulti |
| Lilly USA, LLC | $18.81 | 2025 | Mounjaro, Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $18.48 | 2024 | |
| Vapotherm INC | $18.25 | 2021 | |
| Exact Sciences Corporation | $17.92 | 2025 | The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $14.44 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Steinmetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.